PortViewPortView
Aquestive Therapeutics logo

Aquestive Therapeutics (AQST) Stock Analysis

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

$5.36+2.19%
1-year price historyRange $2.95 – $7.49
52-week range$5.36
$2.93$7.55

What Aquestive Therapeutics does

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

Key metrics

Market cap
$671.88M
P/E (TTM)
-8.24
EPS (TTM)
$-0.65
Beta
1.43
Dividend yield
0.00%
Revenue / share
$0.43
50-day avg
$4.27
200-day avg
$4.47
52-week high
$7.55
52-week low
$2.93
CEO
Daniel Barber

ETFs linked to AQST

Broad-market and Healthcare sector ETFs an investor holding Aquestive Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AQST fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze AQST in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Aquestive Therapeutics?
Aquestive Therapeutics trades under the ticker AQST on NASDAQ.
Which exchange is AQST listed on?
AQST is listed on NASDAQ.
What sector does Aquestive Therapeutics operate in?
Aquestive Therapeutics is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
How can PortView help analyze AQST in a portfolio?
PortView shows AQST's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.